Relmada Therapeutics, Inc. - RLMD STOCK NEWS

Relmada Therapeutics (Nasdaq: RLMD) announced top-line results from a human abuse potential (HAP) study for REL-1017, a novel NMDA receptor channel blocker aimed at treating major depressive disorder (MDD). The study demonstrated that at all tested doses (25 mg, 75 mg, 150 mg), REL-1017 showed a statistically significant difference in likability compared to oxycodone (40 mg), indicating minimal abuse potential. These findings support the ongoing development of REL-1017, highlighting its potential as a safe alternative treatment for MDD. Further data will be submitted to the FDA.

Relmada Therapeutics (Nasdaq: RLMD) has acquired development and commercial rights to a novel psilocybin program from Arbormentis LLC for $15 million upfront, plus potential milestone payments exceeding $150 million. This acquisition, focused on neurological and psychiatric disorders, aligns with Relmada's commitment to advancing CNS treatments. The company’s lead program, REL-1017, is in Phase III for major depressive disorder. The partnership aims to leverage expertise in neuroplasticity to develop innovative therapies addressing mental health challenges.

Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that data on REL-1017, its lead product candidate, will be showcased in two poster presentations at the CPDD 83rd Annual Meeting from June 21 to June 24, 2021. Both presentations, scheduled for June 21, 2021, will detail findings from studies demonstrating that REL-1017 showed no reinforcing properties compared to oxycodone and exhibited no withdrawal effects or physical dependence. REL-1017 is an NMDA receptor channel blocker in late-stage development as a treatment for major depressive disorder (MDD).

Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that CEO Sergio Traversa will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:00 a.m. Eastern Time. Interested parties can access a live webcast of the event through the company's website, where an archived replay will be available for one year. Relmada focuses on major depressive disorder (MDD) and is advancing its lead program, REL-1017, a novel NMDA receptor channel blocker, currently in late-stage development.

Relmada Therapeutics, Inc. (Nasdaq: RLMD) has announced that CEO Sergio Traversa will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 am Eastern Time. The event will provide insights into the company's focus on treating central nervous system diseases, particularly major depressive disorder (MDD), with its lead program, REL-1017, currently in late-stage development. Participants can access the live webcast via the provided links, with an archived replay available for 30 days post-event.

Relmada Therapeutics (Nasdaq: RLMD) announced that clinical data for REL-1017 will be presented at the 2021 ASCP Annual Meeting from June 1-4, 2021. The presentation, titled "REL-1017 is Safe, Well-Tolerated and Exerts Rapid, Robust and Sustained Antidepressant Effects", will feature insights from Marco Pappagallo, MD. REL-1017 aims to provide a rapid-acting, oral antidepressant treatment for major depressive disorder (MDD). The FDA granted Fast Track designation for REL-1017 in April 2017, confirming its promising safety and efficacy profile.

Relmada Therapeutics (RLMD) provided a corporate update and financial results for Q1 2021. The company is advancing its lead product, REL-1017, for major depressive disorder (MDD) through its pivotal Phase 3 trials, RELIANCE I and II, which are currently enrolling participants. The company reported a net loss of $22.2 million for the quarter, up from $10.7 million in Q1 2020, with increased R&D expenses totaling $14 million. Cash reserves decreased to $102.7 million from $117.1 million at year-end 2020. Multiple key clinical data releases are expected in the coming quarters.

Relmada Therapeutics, Inc. (Nasdaq: RLMD) will release its financial results for Q1 2021 after market close on May 12, 2021. A corporate update conference call and audio webcast are scheduled for 4:30 PM ET on the same day. The company focuses on developing treatments for central nervous system diseases, particularly major depressive disorder, with its lead program, REL-1017, currently in late-stage development.

Relmada Therapeutics (Nasdaq: RLMD) announced the presentation of clinical data for its lead product candidate, REL-1017, at the virtual American Psychiatric Association Annual Meeting from May 1-3, 2021. Two posters will be showcased: one on rapid antidepressant effects in Major Depressive Disorder (MDD), and another on therapeutic response related to life-years impacted by MDD. REL-1017, an NMDA receptor channel blocker, is in late-stage studies for adjunctive MDD treatment, with previous trials showing significant efficacy and safety.